Boston, MA 06/18/2014 (wallstreetpr) – Fibrocell Science, Inc., (NYSE MKT:FCSC) on June 17, 2014 announced that it signed an Exclusive License Agreements with The Regents of the University of California.
Highlights of the Agreements
As per the agreement, Fibrocell Science got the autonomy of rights to commercially make use of patented discoveries as well as technologies which are a result of in progress partnership between Fibrocell Science and the University of California at Los Angeles (UCLA).
This Exclusive License Agreements along with the technologies available from UCLA partnership allow Fibrocell Science Inc (NYSEMKT:FCSC) an expansion of the proprietary Personalized Biologics platform that makes use of stem cells and human fibroblasts from the skin in order to create localised therapies. These localised therapies are in turn compatible with every patient’s unique biology. The agreement offers strengthening of the development and research platform of the company.
The agreement is laid down on the foundation of existing research collaboration which at present has yielded technologies as well as discoveries that are associated with the stem cells as well as regenerative cells on the skin of human beings.
Advancements associated with the newly licensed technologies and patents
There are two main kinds of advancements which are associated with the newly licensed technologies as well as patents. These are as follows:
Method of making use of autologous fibroblasts for the purpose of development of personalized biologics having bone morphogenetic protein 2 (BMP-2)
Methods used for production of highly stable and commercially feasible induced pluripotent stem cells (iPSCs) extracted from the adult skin cells.
Statement from the Chairman and CEO of Fibrocell
The Chairman and Chief Executive Officer of Fibrocell Science Inc (NYSEMKT:FCSC), David Pernock said that the technologies which are a result of these licenses will help in strengthening the development platform of Fibrocell. He added that these potentially transformational technologies can offer a lot of other partnering opportunities for Fibrocell.
